Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer.
Cytokine receptors, which exist in membrane-bound and soluble forms, bind their ligands with comparable affinity. Although most soluble receptors are antagonists and compete with their membrane-associated counterparts for the ligands, certain soluble receptors are agonists. In these cases, complexes of ligand and soluble receptor bind on target cells to second receptor subunits and initiate intracellular signaling. The soluble receptors of the interleukin (IL)-6 family of cytokines (sIL-6R, sIL-11R, soluble ciliary neurotrophic factor receptor) are agonists capable of transmitting signals through interaction with the universal signal-transducing receptor for all IL-6 family cytokines, gp130. In vivo, the IL-6/sIL-6R complex stimulates several types of cells, which are unresponsive to IL-6 alone, as they do not express the membrane IL-6R. We have named this process trans-signaling. The generation of soluble cytokine receptors occurs via two distinct mechanisms-limited proteolysis and translation-from differentially spliced mRNA. We have demonstrated that a soluble form of the IL-6 family signaling receptor subunit gp130, which is generated by differential splicing, is the natural inhibitor of IL-6 trans-signaling responses. We have shown that in many chronic inflammatory diseases, including chronic inflammatory bowel disease, peritonitis, rheumatoid arthritis, asthma, as well as colon cancer, IL-6 trans-signaling is critically involved in the maintenance of a disease state, by promoting transition from acute to chronic inflammation. Moreover, in all these models, the course of the disease can be disrupted by specifically interfering with IL-6 trans-signaling using the soluble gp130 protein. The pathophysiological mechanisms by which the IL-6/sIL-6R complex regulates the inflammatory state are discussed.
Rose-John
Stefan
S
Biochemisches Institut, Christian-Albrechts-Universität zu Kiel, Olshausenstr. 40, D-24098 Kiel, Germany. rosejohn@biochem.uni-kiel.de
Scheller
Jürgen
J
Elson
Greg
G
Jones
Simon A
SA
D000818:Animals; D001168:Arthritis / Q000276:immunology / Q000378:metabolism; D001249:Asthma / Q000378:metabolism / Q000628:therapy; D003092:Colitis / Q000378:metabolism; D003110:Colonic Neoplasms / Q000378:metabolism*; D050822:Cytokine Receptor gp130 / Q000502:physiology; D006801:Humans; D007249:Inflammation / Q000378:metabolism*; D015850:Interleukin-6 / Q000378:metabolism / Q000502:physiology*; D051379:Mice; D018448:Models, Immunological; D009369:Neoplasms / Q000378:metabolism*; D011956:Receptors, Cell Surface / Q000378:metabolism*; D019947:Receptors, Interleukin-6 / Q000378:metabolism*; D015398:Signal Transduction; D012995:Solubility
D015850:Interleukin-6; D011956:Receptors, Cell Surface; D019947:Receptors, Interleukin-6; D050822:Cytokine Receptor gp130